Virpax Pharmaceuticals Overview
Virpax Pharmaceuticals (VRPX) has a ROE of 1320.61%, above the Healthcare sector average of 22.76%.
Get informed when a big investor buys or sells
+ Follow1320.61%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, VRPX shows a ROE of 1320.61%. That is above the Healthcare sector average of 22.76%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 22.76%. Virpax Pharmaceuticals is at 1320.61%, which is higher that average. That is roughly 5701.3% above the sector mean. Use the comparison chart on this page to see how VRPX stacks up against individual peers as well.
Check the historical chart to see whether VRPX's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Virpax Pharmaceuticals with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Virpax Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 1320.61%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 22.76%, while VRPX is at 1320.61%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
